{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T01:34:35Z","timestamp":1790818475031,"version":"4.1.0"},"reference-count":134,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100021316","name":"AstraZeneca United States","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021316","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s40273-026-01625-0","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T07:31:04Z","timestamp":1780385464000},"page":"907-935","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A Systematic Literature Review of Health Economic Modelling Approaches Used to Evaluate Treatment Resistant and Uncontrolled Hypertension: A Critical Appraisal and Considerations for the Design of Future Model Analyses"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2774-9439","authenticated-orcid":false,"given":"Matthew","family":"Franklin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8980-2223","authenticated-orcid":false,"given":"James","family":"Fotheringham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3043-6011","authenticated-orcid":false,"given":"Rod S.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1169-3431","authenticated-orcid":false,"given":"Philip A.","family":"Powell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6689-3599","authenticated-orcid":false,"given":"Lise","family":"Retat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieling","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6546-7769","authenticated-orcid":false,"given":"Juan Jose Garcia","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0209-295X","authenticated-orcid":false,"given":"Amy","family":"Gamble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3445-6754","authenticated-orcid":false,"given":"Patrice","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,1]]},"reference":[{"issue":"4","key":"1625_CR1","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41581-019-0244-2","volume":"16","author":"KT Mills","year":"2020","unstructured":"Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol. 2020;16(4):223\u201337.","journal-title":"Nat Rev Nephrol"},{"issue":"10304","key":"1625_CR2","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S0140-6736(21)01330-1","volume":"398","author":"B Zhou","year":"2021","unstructured":"Zhou B, Carrillo-Larco RM, Danaei G, et al. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. The Lancet. 2021;398(10304):957\u201380.","journal-title":"The Lancet"},{"key":"1625_CR3","unstructured":"World Health Organisation. Hypertension. 2025. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hypertension. Accessed 09\/10\/2025."},{"key":"1625_CR4","doi-asserted-by":"publisher","unstructured":"Bourque G, Hiremath S. Rethinking resistant hypertension. J Clin Med. 2022;11(5):1455. https:\/\/doi.org\/10.3390\/jcm11051455.","DOI":"10.3390\/jcm11051455"},{"issue":"12","key":"1625_CR5","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1111\/j.1524-6175.2007.07332.x","volume":"9","author":"AJ Rose","year":"2007","unstructured":"Rose AJ, Berlowitz DR, Orner MB, Kressin NR. Understanding uncontrolled hypertension: is it the patient or the provider? J Clin Hypertens. 2007;9(12):937\u201343.","journal-title":"J Clin Hypertens"},{"issue":"5","key":"1625_CR6","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.1161\/HYP.0000000000000084","volume":"72","author":"RM Carey","year":"2018","unstructured":"Carey RM, Calhoun DA, Bakris GL, et al. Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association. Hypertension. 2018;72(5):e53\u201390.","journal-title":"Hypertension"},{"issue":"13","key":"1625_CR7","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1161\/CIRCULATIONAHA.111.068064","volume":"125","author":"SL Daugherty","year":"2012","unstructured":"Daugherty SL, Powers JD, Magid DJ, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation. 2012;125(13):1635\u201342.","journal-title":"Circulation"},{"issue":"3","key":"1625_CR8","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/ki.2015.142","volume":"88","author":"JJ Sim","year":"2015","unstructured":"Sim JJ, Bhandari SK, Shi J, et al. Comparative risk of renal, cardiovascular, and mortality outcomes in controlled, uncontrolled resistant, and nonresistant hypertension. Kidney Int. 2015;88(3):622\u201332.","journal-title":"Kidney Int"},{"issue":"1","key":"1625_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13643-021-01626-4","volume":"10","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021;10(1):1\u201311.","journal-title":"Syst Rev"},{"key":"1625_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g7647","volume":"350","author":"L Shamseer","year":"2015","unstructured":"Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015;350:g7647.","journal-title":"BMJ"},{"key":"1625_CR11","unstructured":"Carter P, Garcia Sanchez J, Retat L, Coto E, Ouwens M, Solorzano J, Agiro A, Linganathan K, Gait C, Gomes de Freitas P, Song B, Fotheringham J, Franklin M, Powell P, Carlton J, Hill H, Taylor R, Chen J. Economic models and health utility data for treatment resistant and uncontrolled hypertension [CRD42024531565]. 2024. https:\/\/www.crd.york.ac.uk\/PROSPERO\/display_record.php?RecordID=5315652024."},{"key":"1625_CR12","unstructured":"National Institute for Health Research. PROSPERO: International prospective register of systematic reviews 2022 [Internet]. https:\/\/www.crd.york.ac.uk\/PROSPERO\/. Accessed 17 Jan 2024."},{"key":"1625_CR13","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jclinepi.2016.01.021","volume":"75","author":"J McGowan","year":"2016","unstructured":"McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V, Lefebvre C. PRESS peer review of electronic search strategies: 2015 guideline statement. J Clin Epidemiol. 2016;75:40\u20136.","journal-title":"J Clin Epidemiol"},{"issue":"7052","key":"1625_CR14","first-page":"275","volume":"313","author":"MF Drummond","year":"1996","unstructured":"Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ (Clin Res Ed). 1996;313(7052):275\u201383.","journal-title":"BMJ (Clin Res Ed)"},{"key":"1625_CR15","first-page":"09","volume":"09","author":"ASP Sharp","year":"2024","unstructured":"Sharp ASP, Cao KN, Esler MD, et al. Cost-effectiveness of catheter-based radiofrequency renal denervation for the treatment of uncontrolled hypertension: an analysis for the UK based on recent clinical evidence. Eur Heart J Qual Care Clin Outcomes. 2024;09:09.","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"issue":"11","key":"1625_CR16","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1093\/ajh\/hpt099","volume":"26","author":"SM Smith","year":"2013","unstructured":"Smith SM, Campbell JD. Cost-effectiveness of renin-guided treatment of hypertension. Am J Hypertens. 2013;26(11):1303\u201310.","journal-title":"Am J Hypertens"},{"key":"1625_CR17","first-page":"30","volume":"30","author":"RS Taylor","year":"2024","unstructured":"Taylor RS, Bentley A, Metcalfe K, et al. Cost effectiveness of endovascular ultrasound renal denervation in patients with resistant hypertension. Pharmacoeconom Open. 2024;30:30.","journal-title":"Pharmacoeconom Open"},{"issue":"12","key":"1625_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-052884","volume":"11","author":"R Wu","year":"2021","unstructured":"Wu R, Rison SCG, Raisi-Estabragh Z, et al. Gaps in antihypertensive and statin treatments and benefits of optimisation: a modelling study in a 1 million ethnically diverse urban population in UK. BMJ Open. 2021;11(12):e052884.","journal-title":"BMJ Open"},{"issue":"1","key":"1625_CR19","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1080\/13696998.2024.2441072","volume":"28","author":"PA McFarlane","year":"2025","unstructured":"McFarlane PA, Madan M, Ryschon AM, et al. Cost-effectiveness analysis of radiofrequency renal denervation for uncontrolled hypertension in Canada. J Med Econ. 2025;28(1):70\u201380.","journal-title":"J Med Econ"},{"issue":"1","key":"1625_CR20","doi-asserted-by":"publisher","first-page":"2573034","DOI":"10.1080\/08037051.2025.2573034","volume":"34","author":"J Daemen","year":"2025","unstructured":"Daemen J, Saville KA, Ryschon AM, et al. Cost-effectiveness of radiofrequency renal denervation for uncontrolled and resistant hypertension in The Netherlands. Blood Press. 2025;34(1):2573034.","journal-title":"Blood Press"},{"issue":"6","key":"1625_CR21","doi-asserted-by":"publisher","DOI":"10.1111\/jch.70090","volume":"27","author":"H-C Huang","year":"2025","unstructured":"Huang H-C, Cao KN, Ryschon AM, Phay K-W, Wang T-D, Pietzsch JB. Cost-effectiveness of radiofrequency renal denervation in Taiwan based on clinical evidence and regional event rates. J Clin Hypertens Greenwich. 2025;27(6):e70090.","journal-title":"J Clin Hypertens Greenwich"},{"issue":"1","key":"1625_CR22","doi-asserted-by":"publisher","first-page":"2487583","DOI":"10.1080\/08037051.2025.2487583","volume":"34","author":"T Kahan","year":"2025","unstructured":"Kahan T, Johansen ML, Ryschon AM, et al. Cost-effectiveness analysis of radiofrequency renal denervation for uncontrolled hypertension in Sweden. Blood Press. 2025;34(1):2487583.","journal-title":"Blood Press"},{"issue":"10","key":"1625_CR23","volume":"3","author":"DE Kandzari","year":"2024","unstructured":"Kandzari DE, Cao KN, Ryschon AM, Sharp ASP, Pietzsch JB. Catheter-based radiofrequency renal denervation in the United States: a cost-effectiveness analysis based on contemporary evidence. J Soc Cardiovasc Angiogr Interv. 2024;3(10):102234.","journal-title":"J Soc Cardiovasc Angiogr Interv"},{"issue":"12","key":"1625_CR24","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1111\/jch.14922","volume":"26","author":"K Kario","year":"2024","unstructured":"Kario K, Cao KN, Tanaka Y, Ryschon AM, Pietzsch JB. Cost-effectiveness of radiofrequency renal denervation for uncontrolled hypertension in Japan. J Clin Hypertens Greenwich. 2024;26(12):1502\u201312.","journal-title":"J Clin Hypertens Greenwich"},{"issue":"1","key":"1625_CR25","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13561-025-00669-w","volume":"15","author":"D Lian","year":"2025","unstructured":"Lian D, Suo Y, Gai R, et al. Renal denervation for hypertension: cross-country cost-effectiveness insights from mainland China, Japan, and Thailand. Health Econ Rev. 2025;15(1):69.","journal-title":"Health Econ Rev"},{"issue":"6","key":"1625_CR26","volume":"4","author":"RS Taylor","year":"2025","unstructured":"Taylor RS, Murphy K, Kirson N, et al. Cost-utility analysis of endovascular ultrasound renal denervation to treat resistant hypertension in the United States. J Soc Cardiovasc Angiogr Interv. 2025;4(6):103601.","journal-title":"J Soc Cardiovasc Angiogr Interv"},{"issue":"4","key":"1625_CR27","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s41669-025-00574-2","volume":"9","author":"RS Taylor","year":"2025","unstructured":"Taylor RS, Metcalfe K, Cremer A, et al. Cost-effectiveness of ultrasound renal denervation for resistant hypertension in Belgium, France and The Netherlands. Pharmacoeconomics. 2025;9(4):585\u201395.","journal-title":"Pharmacoeconomics"},{"issue":"9","key":"1625_CR28","first-page":"644","volume":"20","author":"I Xursandov","year":"2025","unstructured":"Xursandov I, Raximberganov JR, Rakhmatova M, Jalolova M, Oripov F, Boyjanov N, et al. Cost-effectiveness of renal denervation vs. pharmacotherapy for treatment-resistant hypertension in low-resource settings. Revista Latinoamericana de Hipertensi\u00f3n. 2025;20(9):644.","journal-title":"Revista Latinoamericana de Hipertensi\u00f3n"},{"issue":"8","key":"1625_CR29","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1007\/s11606-015-3231-8","volume":"30","author":"V Fontil","year":"2015","unstructured":"Fontil V, Bibbins-Domingo K, Kazi DS, et al. Simulating strategies for improving control of hypertension among patients with usual source of care in the United States: the blood pressure control model. J Gen Intern Med. 2015;30(8):1147\u201355.","journal-title":"J Gen Intern Med"},{"issue":"2","key":"1625_CR30","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1185\/030079908X260880","volume":"24","author":"JD Belsey","year":"2008","unstructured":"Belsey JD. Switch strategies in the management of hypertension: a cost minimisation analysis of angiotensin receptor blocker based regimen. Curr Med Res Opin. 2008;24(2):581\u20139.","journal-title":"Curr Med Res Opin"},{"issue":"11","key":"1625_CR31","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1038\/s41440-021-00731-0","volume":"44","author":"E Asakura","year":"2021","unstructured":"Asakura E, Ademi Z, Liew D, Zomer E. Productivity burden of hypertension in Japan. Hypertens Res. 2021;44(11):1524\u201333.","journal-title":"Hypertens Res"},{"issue":"4","key":"1625_CR32","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1161\/HYPERTENSIONAHA.118.12606","volume":"73","author":"TR Hird","year":"2019","unstructured":"Hird TR, Zomer E, Owen AJ, Magliano DJ, Liew D, Ademi Z. Productivity burden of hypertension in Australia. Hypertension. 2019;73(4):777\u201384.","journal-title":"Hypertension"},{"issue":"5","key":"1625_CR33","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s40273-023-01251-0","volume":"41","author":"J Roseleur","year":"2023","unstructured":"Roseleur J, Gonzalez-Chica DA, Harvey G, Stocks NP, Karnon J. The cost of uncontrolled blood pressure in Australian general practice: a modelling study using electronic health records (MedicineInsight). Pharmacoeconomics. 2023;41(5):573\u201387.","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"1625_CR34","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-056627","volume":"12","author":"MM Sorato","year":"2022","unstructured":"Sorato MM, Davari M, Kebriaeezadeh A, Sarrafzadegan N, Shibru T. Societal economic burden of hypertension at selected hospitals in southern Ethiopia: a patient-level analysis. BMJ Open. 2022;12(4):e056627.","journal-title":"BMJ Open"},{"issue":"3","key":"1625_CR35","first-page":"e79","volume":"6","author":"K Ogden","year":"2014","unstructured":"Ogden K, Kaila S, Neil N. Single-pill versus loose-dose combination triple therapy for hypertension: formulary impact. Am J Pharm Benefits. 2014;6(3):e79\u201386.","journal-title":"Am J Pharm Benefits"},{"key":"1625_CR36","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j2099","volume":"357","author":"J Hippisley-Cox","year":"2017","unstructured":"Hippisley-Cox J, Coupland C, Brindle P. Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. BMJ. 2017;357:j2099.","journal-title":"BMJ"},{"issue":"3","key":"1625_CR37","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1161\/01.HYP.0000236119.96301.f2","volume":"48","author":"S Julius","year":"2006","unstructured":"Julius S, Weber MA, Kjeldsen SE, et al. The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial. Hypertension. 2006;48(3):385\u201391.","journal-title":"Hypertension"},{"issue":"9426","key":"1625_CR38","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1016\/S0140-6736(04)16451-9","volume":"363","author":"S Julius","year":"2004","unstructured":"Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. The Lancet. 2004;363(9426):2022\u201331.","journal-title":"The Lancet"},{"key":"1625_CR39","doi-asserted-by":"crossref","unstructured":"Turkson AJ. A closer look at the Kaplan\u2013Meier and life table models in survival analysis. OALib. 2021.","DOI":"10.4236\/oalib.1108104"},{"issue":"Suppl 1","key":"1625_CR40","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2165\/00019053-200321001-00004","volume":"21","author":"A Lloyd","year":"2003","unstructured":"Lloyd A, Schmieder C, Marchant N. Financial and health costs of uncontrolled blood pressure in the United Kingdom. Pharmacoeconomics. 2003;21(Suppl 1):33\u201341.","journal-title":"Pharmacoeconomics"},{"issue":"10293","key":"1625_CR41","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1016\/S0140-6736(21)00788-1","volume":"397","author":"M Azizi","year":"2021","unstructured":"Azizi M, Sanghvi K, Saxena M, et al. Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial. Lancet. 2021;397(10293):2476\u201386.","journal-title":"Lancet"},{"issue":"19","key":"1625_CR42","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1016\/j.jacc.2023.08.045","volume":"82","author":"DE Kandzari","year":"2023","unstructured":"Kandzari DE, Townsend RR, Kario K, et al. Safety and efficacy of renal denervation in patients taking antihypertensive medications. J Am Coll Cardiol. 2023;82(19):1809\u201323.","journal-title":"J Am Coll Cardiol"},{"issue":"44","key":"1625_CR43","doi-asserted-by":"publisher","first-page":"4761","DOI":"10.1093\/eurheartj\/ehae703","volume":"45","author":"Y Li","year":"2024","unstructured":"Li Y, Gao F, Ren C, et al. The Netrod\u2122 six-electrode radiofrequency renal denervation system for uncontrolled hypertension: a sham-controlled trial. Eur Heart J. 2024;45(44):4761\u20134.","journal-title":"Eur Heart J"},{"issue":"7","key":"1625_CR44","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1038\/ajh.2009.63","volume":"22","author":"BM Egan","year":"2009","unstructured":"Egan BM, Basile JN, Rehman SU, et al. Plasma Renin test-guided drug treatment algorithm for correcting patients with treated but uncontrolled hypertension: a randomized controlled trial. Am J Hypertens. 2009;22(7):792\u2013801.","journal-title":"Am J Hypertens"},{"issue":"12","key":"1625_CR45","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1097\/HJH.0000000000000378","volume":"32","author":"C Thomopoulos","year":"2014","unstructured":"Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta-analyses, and meta-regression analyses of randomized trials. J Hypertens. 2014;32(12):2285\u201395.","journal-title":"J Hypertens"},{"key":"1625_CR46","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f5680","volume":"347","author":"Collaboration BPLTT","year":"2013","unstructured":"Collaboration BPLTT. Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials. BMJ Br Med J. 2013;347:f5680.","journal-title":"BMJ Br Med J"},{"issue":"5","key":"1625_CR47","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1007\/s11427-018-9281-6","volume":"61","author":"C Han","year":"2018","unstructured":"Han C, Liu F, Yang X, et al. Ideal cardiovascular health and incidence of atherosclerotic cardiovascular disease among Chinese adults: the China-PAR project. Sci China Life Sci. 2018;61(5):504\u201314.","journal-title":"Sci China Life Sci"},{"issue":"2 Pt 1","key":"1625_CR48","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/S0002-8703(00)90236-9","volume":"139","author":"RB D'Agostino","year":"2000","unstructured":"D\u2019Agostino RB, Russell MW, Huse DM, et al. Primary and subsequent coronary risk appraisal: new results from the Framingham study. Am Heart J. 2000;139(2 Pt 1):272\u201381.","journal-title":"Am Heart J"},{"issue":"3","key":"1625_CR49","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1161\/01.STR.22.3.312","volume":"22","author":"PA Wolf","year":"1991","unstructured":"Wolf PA, D\u2019Agostino RB, Belanger AJ, Kannel WB. Probability of stroke: a risk profile from the Framingham study. Stroke. 1991;22(3):312\u20138.","journal-title":"Stroke"},{"issue":"20","key":"1625_CR50","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1161\/CIRCULATIONAHA.108.784215","volume":"118","author":"RS Velagaleti","year":"2008","unstructured":"Velagaleti RS, Pencina MJ, Murabito JM, et al. Long-term trends in the incidence of heart failure after myocardial infarction. Circulation. 2008;118(20):2057\u201362.","journal-title":"Circulation"},{"issue":"6","key":"1625_CR51","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1093\/ije\/31.6.1253","volume":"31","author":"R Voss","year":"2002","unstructured":"Voss R, Cullen P, Schulte H, Assmann G. Prediction of risk of coronary events in middle-aged men in the Prospective Cardiovascular M\u00fcnster Study (PROCAM) using neural networks. Int J Epidemiol. 2002;31(6):1253\u201362 (discussion 62\u201364).","journal-title":"Int J Epidemiol"},{"issue":"11","key":"1625_CR52","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1001\/archinte.159.11.1197","volume":"159","author":"WB Kannel","year":"1999","unstructured":"Kannel WB, D\u2019Agostino RB, Silbershatz H, Belanger AJ, Wilson PW, Levy D. Profile for estimating risk of heart failure. Arch Intern Med. 1999;159(11):1197\u2013204.","journal-title":"Arch Intern Med"},{"issue":"1","key":"1625_CR53","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1161\/01.STR.25.1.40","volume":"25","author":"RB D'Agostino","year":"1994","unstructured":"D\u2019Agostino RB, Wolf PA, Belanger AJ, Kannel WB. Stroke risk profile: adjustment for antihypertensive medication. The Framingham study. Stroke. 1994;25(1):40\u20133.","journal-title":"Stroke"},{"issue":"1 Pt 2","key":"1625_CR54","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/0002-8703(91)90861-B","volume":"121","author":"KM Anderson","year":"1991","unstructured":"Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular disease risk profiles. Am Heart J. 1991;121(1 Pt 2):293\u20138.","journal-title":"Am Heart J"},{"issue":"19","key":"1625_CR55","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1161\/CIRCULATIONAHA.116.022367","volume":"134","author":"X Yang","year":"2016","unstructured":"Yang X, Li J, Hu D, et al. Predicting the 10-year risks of atherosclerotic cardiovascular disease in Chinese population: the China-PAR Project (Prediction for ASCVD Risk in China). Circulation. 2016;134(19):1430\u201340.","journal-title":"Circulation"},{"issue":"9","key":"1625_CR56","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1161\/STROKEAHA.119.025553","volume":"50","author":"X Xing","year":"2019","unstructured":"Xing X, Yang X, Liu F, et al. Predicting 10-year and lifetime stroke risk in Chinese population. Stroke. 2019;50(9):2371\u20138.","journal-title":"Stroke"},{"issue":"8","key":"1625_CR57","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1161\/STROKEAHA.107.510362","volume":"39","author":"G Saposnik","year":"2008","unstructured":"Saposnik G, Hill MD, O\u2019Donnell M, Fang J, Hachinski V, Kapral MK. Variables associated with 7-day, 30-day, and 1-year fatality after ischemic stroke. Stroke. 2008;39(8):2318\u201324.","journal-title":"Stroke"},{"issue":"12","key":"1625_CR58","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1007\/s40273-022-01182-2","volume":"40","author":"X Dong","year":"2022","unstructured":"Dong X, He X, Wu J. Cost effectiveness of the first\u2010in\u2010class ARNI (Sacubitril\/Valsartan) for the treatment of essential hypertension in a Chinese setting. Pharmacoeconomics. 2022;40(12):1187\u2013205.","journal-title":"Pharmacoeconomics"},{"issue":"14","key":"1625_CR59","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.jacc.2012.07.029","volume":"60","author":"BP Geisler","year":"2012","unstructured":"Geisler BP, Egan BM, Cohen JT, et al. Cost-effectiveness and clinical effectiveness of catheter-based renal denervation for resistant hypertension. J Am Coll Cardiol. 2012;60(14):1271\u20137.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"1625_CR60","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1111\/j.1524-4733.2010.00700.x","volume":"13","author":"R Ara","year":"2010","unstructured":"Ara R, Brazier JE. Populating an economic model with health state utility values: moving toward better practice. Value Health. 2010;13(5):509\u201318.","journal-title":"Value Health"},{"issue":"2","key":"1625_CR61","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.ahj.2010.05.008","volume":"160","author":"M Aasa","year":"2010","unstructured":"Aasa M, Henriksson M, Dellborg M, et al. Cost and health outcome of primary percutaneous coronary intervention versus thrombolysis in acute ST-segment elevation myocardial infarction-Results of the Swedish Early Decision reperfusion study (SWEDES) trial. Am Heart J. 2010;160(2):322\u20138.","journal-title":"Am Heart J"},{"issue":"1","key":"1625_CR62","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1477-7525-5-21","volume":"5","author":"P Glasziou","year":"2007","unstructured":"Glasziou P, Alexander J, Beller E, Clarke P, the ACG. Which health-related quality of life score? A comparison of alternative utility measures in patients with Type 2 diabetes in the ADVANCE trial. Health Qual Life Outcomes. 2007;5(1):21.","journal-title":"Health Qual Life Outcomes"},{"issue":"14","key":"1625_CR63","doi-asserted-by":"publisher","first-page":"178","DOI":"10.3310\/hta11140","volume":"11","author":"S Ward","year":"2007","unstructured":"Ward S, Lloyd Jones M, Pandor A, et al. A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess. 2007;11(14):178.","journal-title":"Health Technol Assess"},{"issue":"3","key":"1625_CR64","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/j.1742-1241.2011.02633.x","volume":"65","author":"AM Grosso","year":"2011","unstructured":"Grosso AM, Bodalia PN, Macallister RJ, Hingorani AD, Moon JC, Scott MA. Comparative clinical- and cost-effectiveness of candesartan and losartan in the management of hypertension and heart failure: a systematic review, meta- and cost-utility analysis. Int J Clin Pract. 2011;65(3):253\u201363.","journal-title":"Int J Clin Pract"},{"issue":"3","key":"1625_CR65","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1001\/archinte.167.3.290","volume":"167","author":"M Pignone","year":"2007","unstructured":"Pignone M, Earnshaw S, Pletcher MJ, Tice JA. Aspirin for the primary prevention of cardiovascular disease in women: a cost-utility analysis. Arch Intern Med. 2007;167(3):290\u20135.","journal-title":"Arch Intern Med"},{"issue":"1","key":"1625_CR66","doi-asserted-by":"publisher","first-page":"76","DOI":"10.3111\/13696998.2014.978453","volume":"18","author":"TL Henry","year":"2015","unstructured":"Henry TL, De Brouwer BFE, Van Keep MML, Blankestijn PJ, Bots ML, Koffijberg H. Cost-effectiveness of renal denervation therapy for the treatment of resistant hypertension in The Netherlands. J Med Econ. 2015;18(1):76\u201387.","journal-title":"J Med Econ"},{"issue":"5-6","key":"1625_CR67","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1159\/000101463","volume":"23","author":"A-SE Darlington","year":"2007","unstructured":"Darlington A-SE, Dippel DWJ, Ribbers GM, van Balen R, Passchier J, Busschbach JJV. Coping strategies as determinants of quality of life in stroke patients: a longitudinal study. Cerebrovasc Dis. 2007;23(5\u20136):401\u20137.","journal-title":"Cerebrovasc Dis"},{"issue":"1","key":"1625_CR68","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-27377-2","volume":"8","author":"D Zhou","year":"2018","unstructured":"Zhou D, Xi B, Zhao M, Wang L, Veeranki SP. Uncontrolled hypertension increases risk of all-cause and cardiovascular disease mortality in US adults: the NHANES III Linked Mortality study. Sci Rep. 2018;8(1):9418.","journal-title":"Sci Rep"},{"issue":"6","key":"1625_CR69","first-page":"1741","volume":"48","author":"D Busingye","year":"2019","unstructured":"Busingye D, Gianacas C, Pollack A, et al. Data resource profile: MedicineInsight, an Australian national primary health care database. Int J Epidemiol. 2019;48(6):1741-h.","journal-title":"Int J Epidemiol"},{"issue":"10022","key":"1625_CR70","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","volume":"387","author":"D Ettehad","year":"2016","unstructured":"Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. The Lancet. 2016;387(10022):957\u201367.","journal-title":"The Lancet"},{"issue":"6","key":"1625_CR71","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.107.699579","volume":"117","author":"RB D'Agostino Sr","year":"2008","unstructured":"D\u2019Agostino RB Sr, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart study. Circulation. 2008;117(6):743\u201353.","journal-title":"Circulation"},{"issue":"10","key":"1625_CR72","doi-asserted-by":"publisher","first-page":"e1332","DOI":"10.1016\/S2214-109X(19)30318-3","volume":"7","author":"WHO","year":"2019","unstructured":"WHO. World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions. Lancet Glob Health. 2019;7(10):e1332\u201345.","journal-title":"Lancet Glob Health"},{"key":"1625_CR73","unstructured":"Statistics Bureau of Japan MoIAaC. The Statistical Yearbook 2020. Chapter 2 population and households. Table 2-22 Life table. 2020. https:\/\/www.stat.go.jp\/english\/data\/nenkan\/69nenkan\/1431-02.html. Accessed 08\/05\/2025."},{"key":"1625_CR74","unstructured":"Australian Institute of Health and Welfare. General Record of Incidence of Mortality (GRIM) books. 09\/04\/2025 2018. https:\/\/www.aihw.gov.au\/reports\/life-expectancy-deaths\/grim-books\/contents\/grim-excel-workbooks. Accessed 08\/05\/2025."},{"issue":"11","key":"1625_CR75","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1093\/aje\/kww112","volume":"184","author":"BA Goldstein","year":"2016","unstructured":"Goldstein BA, Bhavsar NA, Phelan M, Pencina MJ. Controlling for informed presence bias due to the number of health encounters in an electronic health record. Am J Epidemiol. 2016;184(11):847\u201355.","journal-title":"Am J Epidemiol"},{"key":"1625_CR76","unstructured":"National Heart Foundation of Australia. Economic cost of acute coronary syndrome in Australia: the cost to governments. 2018."},{"issue":"10","key":"1625_CR77","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1016\/j.hlc.2021.04.016","volume":"30","author":"SL Smith","year":"2021","unstructured":"Smith SL, Norman R, Moxon JV, Velu R, Quigley F, Golledge J. Outcomes and costs of open and endovascular revascularisation for chronic limb ischaemia in an Australian cohort. Heart Lung Circ. 2021;30(10):1552\u201361.","journal-title":"Heart Lung Circ"},{"issue":"8","key":"1625_CR78","first-page":"568","volume":"16","author":"DG Pittman","year":"2010","unstructured":"Pittman DG, Tao Z, Chen W, Stettin GD. Antihypertensive medication adherence and subsequent healthcare utilization and costs. Am J Manag Care. 2010;16(8):568\u201376.","journal-title":"Am J Manag Care"},{"issue":"2","key":"1625_CR79","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.032370","volume":"13","author":"F Zhang","year":"2024","unstructured":"Zhang F, Bryant KB, Moran AE, et al. Effectiveness of hypertension management strategies in SPRINT-eligible US adults: a simulation study. J Am Heart Assoc. 2024;13(2):e032370.","journal-title":"J Am Heart Assoc"},{"key":"1625_CR80","unstructured":"NICE. The guidelines manual: NICE process and methods. 2012. https:\/\/www.nice.org.uk\/process\/pmg6\/chapter\/assessing-cost-effectiveness. Accessed 02\/07\/2025."},{"key":"1625_CR81","unstructured":"NICE. Developing NICE guidelines: the manual. 29\/05\/2024 2014. https:\/\/www.nice.org.uk\/process\/pmg20\/chapter\/incorporating-economic-evaluation. Accessed 02\/07\/2025."},{"issue":"5","key":"1625_CR82","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/j.1524-4733.2007.00187.x","volume":"10","author":"JA Mauskopf","year":"2007","unstructured":"Mauskopf JA, Sullivan SD, Annemans L, et al. Principles of good practice for budget impact analysis: report of the ISPOR task force on good research practices\u2014budget impact analysis. Value Health. 2007;10(5):336\u201347.","journal-title":"Value Health"},{"issue":"1","key":"1625_CR83","doi-asserted-by":"publisher","DOI":"10.1017\/S0266462323000193","volume":"39","author":"L Schnitzler","year":"2023","unstructured":"Schnitzler L, Roberts TE, Jackson LJ, Paulus ATG, Evers SMAA. A consensus-based checklist for the critical appraisal of cost-of-illness (COI) studies. Int J Technol Assess Health Care. 2023;39(1):e34.","journal-title":"Int J Technol Assess Health Care"},{"issue":"19","key":"1625_CR84","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1016\/j.jacc.2019.02.057","volume":"73","author":"SS Khan","year":"2019","unstructured":"Khan SS, Ning H, Shah SJ, et al. 10-Year risk equations for incident heart failure in the general population. J Am Coll Cardiol. 2019;73(19):2388\u201397.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"1625_CR85","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1053\/j.ajkd.2018.12.044","volume":"74","author":"E Ku","year":"2019","unstructured":"Ku E, Lee BJ, Wei J, Weir MR. Hypertension in CKD: core curriculum 2019. Am J Kidney Dis. 2019;74(1):120\u201331.","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"1625_CR86","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1161\/HYPERTENSIONAHA.121.18502","volume":"79","author":"RS Vasan","year":"2022","unstructured":"Vasan RS, Song RJ, Xanthakis V, et al. Hypertension-mediated organ damage: prevalence, correlates, and prognosis in the community. Hypertension. 2022;79(3):505\u201315.","journal-title":"Hypertension"},{"issue":"5","key":"1625_CR87","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1161\/HYPERTENSIONAHA.123.21356","volume":"81","author":"A Pacholko","year":"2024","unstructured":"Pacholko A, Iadecola C. Hypertension, neurodegeneration, and cognitive decline. Hypertension. 2024;81(5):991\u20131007.","journal-title":"Hypertension"},{"issue":"3","key":"1625_CR88","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1097\/HJH.0000000000003653","volume":"42","author":"A Kollias","year":"2024","unstructured":"Kollias A, Kyriakoulis KG, Komnianou A, Stathopoulou P, Stergiou GS. Prognostic value of home versus ambulatory blood pressure monitoring: a systematic review and meta-analysis of outcome studies. J Hypertens. 2024;42(3):385\u201392.","journal-title":"J Hypertens"},{"issue":"10393","key":"1625_CR89","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1016\/S0140-6736(23)00733-X","volume":"401","author":"N Staplin","year":"2023","unstructured":"Staplin N, de la Sierra A, Ruilope LM, et al. Relationship between clinic and ambulatory blood pressure and mortality: an observational cohort study in 59 124 patients. The Lancet. 2023;401(10393):2041\u201350.","journal-title":"The Lancet"},{"issue":"1","key":"1625_CR90","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13104-019-4067-9","volume":"12","author":"C Gerlinger","year":"2019","unstructured":"Gerlinger C, Bamber L, Leverkus F, et al. Comparing the EQ-5D-5L utility index based on value sets of different countries: impact on the interpretation of clinical study results. BMC Res Notes. 2019;12(1):18.","journal-title":"BMC Res Notes"},{"issue":"3","key":"1625_CR91","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s40273-020-00999-z","volume":"39","author":"Z Ademi","year":"2021","unstructured":"Ademi Z, Ackerman IN, Zomer E, Liew D. Productivity-adjusted life-years: a new metric for quantifying disease burden. Pharmacoeconomics. 2021;39(3):271\u20133.","journal-title":"Pharmacoeconomics"},{"key":"1625_CR92","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhealeco.2024.102885","volume":"95","author":"KS Hansen","year":"2024","unstructured":"Hansen KS, Moreno-Ternero JD, \u00d8sterdal LP. Quality- and productivity-adjusted life years: from QALYs to PALYs and beyond. J Health Econ. 2024;95:102885.","journal-title":"J Health Econ"},{"issue":"6","key":"1625_CR93","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1161\/HYPERTENSIONAHA.120.15026","volume":"75","author":"T Unger","year":"2020","unstructured":"Unger T, Borghi C, Charchar F, et al. 2020 International Society of Hypertension Global Hypertension practice guidelines. Hypertension. 2020;75(6):1334\u201357.","journal-title":"Hypertension"},{"key":"1625_CR94","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.jclinepi.2021.04.012","volume":"137","author":"AI Dobrescu","year":"2021","unstructured":"Dobrescu AI, Nussbaumer-Streit B, Klerings I, et al. Restricting evidence syntheses of interventions to English-language publications is a viable methodological shortcut for most medical topics: a systematic review. J Clin Epidemiol. 2021;137:209\u201317.","journal-title":"J Clin Epidemiol"},{"key":"1625_CR95","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jclinepi.2019.10.011","volume":"118","author":"B Nussbaumer-Streit","year":"2020","unstructured":"Nussbaumer-Streit B, Klerings I, Dobrescu AI, et al. Excluding non-English publications from evidence-syntheses did not change conclusions: a meta-epidemiological study. J Clin Epidemiol. 2020;118:42\u201354.","journal-title":"J Clin Epidemiol"},{"key":"1625_CR96","unstructured":"Carter PMG, Garcia Sanchez JJ, Jackson D, Norris T, Ouwens M, Jarbrink K, Coto E, Papas M, Solozano J, Eryd SA, Hill H, Franklin M, Fotheringham J. Risk equations for adverse clinical events in people with treatment resistant or uncontrolled hypertension. Under development. 2024."},{"key":"1625_CR97","doi-asserted-by":"crossref","unstructured":"Turner HC, Archer RA, Downey LE, et al. An introduction to the main types of economic evaluations used for informing priority setting and resource allocation in healthcare: key features, uses, and limitations. Front Public Health. 2021;9-2021.","DOI":"10.3389\/fpubh.2021.722927"},{"issue":"4","key":"1625_CR98","doi-asserted-by":"publisher","first-page":"327","DOI":"10.3350\/cmh.2014.20.4.327","volume":"20","author":"C Jo","year":"2014","unstructured":"Jo C. Cost-of-illness studies: concepts, scopes, and methods. Clin Mol Hepatol. 2014;20(4):327\u201337.","journal-title":"Clin Mol Hepatol"},{"issue":"1","key":"1625_CR99","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.jval.2013.08.2291","volume":"17","author":"SD Sullivan","year":"2014","unstructured":"Sullivan SD, Mauskopf JA, Augustovski F, et al. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value Health. 2014;17(1):5\u201314.","journal-title":"Value Health"},{"issue":"1","key":"1625_CR100","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1477-7525-8-13","volume":"8","author":"MTD Dyer","year":"2010","unstructured":"Dyer MTD, Goldsmith KA, Sharples LS, Buxton MJ. A review of health utilities using the EQ-5D in studies of cardiovascular disease. Health Qual Life Outcomes. 2010;8(1):13.","journal-title":"Health Qual Life Outcomes"},{"issue":"8","key":"1625_CR101","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1016\/j.jval.2021.03.010","volume":"24","author":"T Shiroiwa","year":"2021","unstructured":"Shiroiwa T, Noto S, Fukuda T. Japanese population norms of EQ-5D-5L and Health Utilities Index Mark 3: disutility catalog by disease and symptom in community settings. Value Health. 2021;24(8):1193\u2013202.","journal-title":"Value Health"},{"issue":"1","key":"1625_CR102","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1477-7525-5-13","volume":"5","author":"A Kiessling","year":"2007","unstructured":"Kiessling A, Henriksson P. Time trends of chest pain symptoms and health related quality of life in coronary artery disease. Health Qual Life Outcomes. 2007;5(1):13.","journal-title":"Health Qual Life Outcomes"},{"issue":"4","key":"1625_CR103","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1177\/0272989X06290496","volume":"26","author":"PW Sullivan","year":"2006","unstructured":"Sullivan PW, Ghushchyan V. Mapping the EQ-5D index from the SF-12: US general population preferences in a nationally representative sample. Med Decis Mak. 2006;26(4):401\u20139.","journal-title":"Med Decis Mak"},{"issue":"3","key":"1625_CR104","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1177\/1715163517701109","volume":"150","author":"C Marra","year":"2017","unstructured":"Marra C, Johnston K, Santschi V, Tsuyuki RT. Cost-effectiveness of pharmacist care for managing hypertension in Canada. Can Pharm J Ott. 2017;150(3):184\u201397.","journal-title":"Can Pharm J Ott"},{"issue":"7434","key":"1625_CR105","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1136\/bmj.37956.664236.EE","volume":"328","author":"S Goodacre","year":"2004","unstructured":"Goodacre S, Nicholl J, Dixon S, et al. Randomised controlled trial and economic evaluation of a chest pain observation unit compared with routine care. BMJ. 2004;328(7434):254.","journal-title":"BMJ"},{"issue":"6","key":"1625_CR106","doi-asserted-by":"publisher","first-page":"2801","DOI":"10.1111\/j.1523-1755.2005.00752.x","volume":"68","author":"I Gorodetskaya","year":"2005","unstructured":"Gorodetskaya I, Zenios S, McCulloch CE, et al. Health-related quality of life and estimates of utility in chronic kidney disease. Kidney Int. 2005;68(6):2801\u20138.","journal-title":"Kidney Int"},{"issue":"1","key":"1625_CR107","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.jcrc.2014.09.009","volume":"30","author":"IW Soliman","year":"2015","unstructured":"Soliman IW, de Lange DW, Peelen LM, et al. Single-center large-cohort study into quality of life in Dutch intensive care unit subgroups, 1 year after admission, using EuroQoL EQ-6D-3L. J Crit Care. 2015;30(1):181\u20136.","journal-title":"J Crit Care"},{"issue":"1","key":"1625_CR108","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1177\/089686080202200107","volume":"22","author":"K Sennf\u00e4lt","year":"2002","unstructured":"Sennf\u00e4lt K, Magnusson M, Carlsson P. Comparison of hemodialysis and peritoneal dialysis\u2014a cost-utility analysis. Perit Dial Int. 2002;22(1):39\u201347.","journal-title":"Perit Dial Int"},{"issue":"11","key":"1625_CR109","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1093\/ndt\/gfad151","volume":"38","author":"J Wijkstr\u00f6m","year":"2023","unstructured":"Wijkstr\u00f6m J, Caldinelli A, Bruchfeld A, et al. Results of the first nationwide cohort study of outcomes in dialysis and kidney transplant patients before and after vaccination for COVID-19. Nephrol Dial Transplant. 2023;38(11):2607\u201316.","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"1625_CR110","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1111\/j.1524-4733.2008.00401.x","volume":"12","author":"CP Lee","year":"2009","unstructured":"Lee CP, Chertow GM, Zenios SA. An empiric estimate of the value of life: updating the renal dialysis cost-effectiveness standard. Value Health. 2009;12(1):80\u20137.","journal-title":"Value Health"},{"issue":"2","key":"1625_CR111","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-039653","volume":"11","author":"F Yang","year":"2021","unstructured":"Yang F, Liao M, Wang P, Liu Y. Cost-effectiveness analysis of renal replacement therapy strategies in Guangzhou city, southern China. BMJ Open. 2021;11(2):e039653.","journal-title":"BMJ Open"},{"key":"1625_CR112","doi-asserted-by":"crossref","unstructured":"Albuquerque de Almeida F, Al MJ, Koymans R, Riistama J, Pauws S, Severens JL. Impact of hospitalisation on health-related quality of life in patients with chronic heart failure. Health Quality Life Outcomes. 2020;18(1): 262.","DOI":"10.1186\/s12955-020-01508-8"},{"issue":"6","key":"1625_CR113","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.3390\/jpm13061001","volume":"13","author":"S-T Wang","year":"2023","unstructured":"Wang S-T, Lin T-Y, Chen TH-H, Chen SL-S, Fann JC-Y. Cost-effectiveness analysis of personalized hypertension prevention. J Personal Med. 2023;13(6):1001.","journal-title":"J Personal Med"},{"issue":"1","key":"1625_CR114","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s41687-020-00216-7","volume":"4","author":"\u00c5 Jonsson","year":"2020","unstructured":"Jonsson \u00c5, Orwelius L, Dahlstrom U, Kristenson M. Evaluation of the usefulness of EQ-5D as a patient-reported outcome measure using the Paretian classification of health change among patients with chronic heart failure. J Patient Rep Outcomes. 2020;4(1):50.","journal-title":"J Patient Rep Outcomes"},{"issue":"2","key":"1625_CR115","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1023\/B:CARD.0000029034.65769.f7","volume":"18","author":"L Chen","year":"2004","unstructured":"Chen L, Hay JW. Cost-effectiveness of primary implanted cardioverter defibrillator for sudden death prevention in congestive heart failure. Cardiovasc Drugs Ther. 2004;18(2):161\u201370.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"2","key":"1625_CR116","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1177\/0272989X9301300202","volume":"13","author":"DG Fryback","year":"1993","unstructured":"Fryback DG, Dasbach EJ, Klein R, et al. The Beaver Dam Health Outcomes study: initial catalog of health-state quality factors. Med Decis Making. 1993;13(2):89\u2013102.","journal-title":"Med Decis Making"},{"issue":"1","key":"1625_CR117","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1093\/eurheartj\/ehr504","volume":"34","author":"J Comin-Colet","year":"2012","unstructured":"Comin-Colet J, Lainscak M, Dickstein K, et al. The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency: a subanalysis of the FAIR-HF study. Eur Heart J. 2012;34(1):30\u20138.","journal-title":"Eur Heart J"},{"issue":"1","key":"1625_CR118","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1186\/s12955-021-01879-6","volume":"19","author":"S Sang","year":"2021","unstructured":"Sang S, Kang N, Liao W, et al. The influencing factors of health-related quality of life among rural hypertensive individuals: a cross-sectional study. Health Qual Life Outcomes. 2021;19(1):244.","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"1625_CR119","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12955-016-0577-5","volume":"15","author":"MJ-J Mangen","year":"2017","unstructured":"Mangen MJ-J, Bolkenbaas M, Huijts SM, van Werkhoven CH, Bonten MJM, de Wit GA. Quality of life in community-dwelling Dutch elderly measured by EQ-5D-3L. Health Quality Life Outcomes. 2017;15(1):3.","journal-title":"Health Quality Life Outcomes"},{"issue":"6","key":"1625_CR120","first-page":"491","volume":"11","author":"S Humphries","year":"2022","unstructured":"Humphries S, Wallert J, Mars K, Held C, Hofmann R, Olsson EMG. Association between \u03b2-blocker dose and quality of life after myocardial infarction: a real-world Swedish register-linked study. Eur Heart J Acute Cardiovasc Care. 2022;11(6):491\u2013500.","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"issue":"11","key":"1625_CR121","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-008220","volume":"5","author":"M van Eeden","year":"2015","unstructured":"van Eeden M, van Heugten C, van Mastrigt GAPG, van Mierlo M, Visser-Meily JMA, Evers SMAA. The burden of stroke in the Netherlands: estimating quality of life and costs for 1 year poststroke. BMJ Open. 2015;5(11):e008220.","journal-title":"BMJ Open"},{"issue":"4","key":"1625_CR122","doi-asserted-by":"publisher","first-page":"346","DOI":"10.2340\/16501977-2069","volume":"48","author":"W-S Lu","year":"2016","unstructured":"Lu W-S, Huang S-L, Yang J-F, Chen M-H, Hsieh C-L, Chou C-Y. Convergent validity and responsiveness of the EQ-5D utility weights for stroke survivors. J Rehabil Med. 2016;48(4):346\u201351.","journal-title":"J Rehabil Med"},{"issue":"2","key":"1625_CR123","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1097\/HJR.0b013e3282f37a22","volume":"15","author":"P Lindgren","year":"2008","unstructured":"Lindgren P, Glader E-L, J\u00f6nsson B. Utility loss and indirect costs after stroke in Sweden. Eur J Cardiovasc Prev Rehabil. 2008;15(2):230\u20133.","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"issue":"3","key":"1625_CR124","doi-asserted-by":"publisher","first-page":"191","DOI":"10.2165\/00019053-200321030-00004","volume":"21","author":"TO Tengs","year":"2003","unstructured":"Tengs TO, Lin TH. A meta-analysis of quality-of-life estimates for stroke. Pharmacoeconomics. 2003;21(3):191\u2013200.","journal-title":"Pharmacoeconomics"},{"key":"1625_CR125","unstructured":"Zorginstitutt Nederland. Guideline for economic evaluations in healthcare. 2024. https:\/\/english.zorginstituutnederland.nl\/documents\/2024\/01\/16\/guideline-for-economic-evaluations-in-healthcare."},{"key":"1625_CR126","volume-title":"Making choices in health: WHO guide to cost-effectiveness analysis","author":"TT-T Edejer","year":"2003","unstructured":"Edejer TT-T, World Health O. Making choices in health: WHO guide to cost-effectiveness analysis. Geneva: World Health Organization; 2003."},{"issue":"11","key":"1625_CR127","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1007\/s40273-015-0307-6","volume":"33","author":"M Svensson","year":"2015","unstructured":"Svensson M, Nilsson FOL, Arnberg K. Reimbursement decisions for pharmaceuticals in Sweden: the impact of disease severity and cost effectiveness. Pharmacoeconomics. 2015;33(11):1229\u201336.","journal-title":"Pharmacoeconomics"},{"issue":"21","key":"1625_CR128","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1016\/j.jacc.2014.03.016","volume":"63","author":"JL Anderson","year":"2014","unstructured":"Anderson JL, Heidenreich PA, Barnett PG, et al. ACC\/AHA statement on cost\/value methodology in clinical practice guidelines and performance measures. J Am Coll Cardiol. 2014;63(21):2304\u201322.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"1625_CR129","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jval.2019.10.005","volume":"23","author":"M Hasegawa","year":"2020","unstructured":"Hasegawa M, Komoto S, Shiroiwa T, Fukuda T. Formal implementation of cost-effectiveness evaluations in Japan: a unique health technology assessment system. Value Health. 2020;23(1):43\u201351.","journal-title":"Value Health"},{"key":"1625_CR130","unstructured":"Center for Outcomes Research and Economic Evaluation for Health NIoPHCH. Guideline for preparing cost-effectiveness evaluation to the Central Social InsuranceMedical Council. 2022. https:\/\/c2h.niph.go.jp\/tools\/guideline\/guideline_en.pdf."},{"key":"1625_CR131","unstructured":"Guidelines CMa. Guidelines for the Economic Evaluation of Health Technolgogies: Canada. 2017. https:\/\/www.cda-amc.ca\/sites\/default\/files\/pdf\/guidelines_for_the_economic_evaluation_of_health_technologies_canada_4th_ed.pdf."},{"key":"1625_CR132","unstructured":"National Institute for Health Research. NICE technology appraisal and highly specialised technologies guidance: the manual. 2022. https:\/\/www.nice.org.uk\/process\/pmg36."},{"key":"1625_CR133","unstructured":"Belgian Health Care Knowledge Centre (KCE). Belgian guidelines for economic evaluations and budget impact analyses. https:\/\/kce.fgov.be\/en\/belgian-guidelines-for-economic-evaluations-and-budget-impact-analyses-third-edition."},{"key":"1625_CR134","unstructured":"Haute Autorite De Sante (HAS). Choices in methods for economic evaluation. 2020. https:\/\/www.has-sante.fr\/jcms\/r_1499251\/en\/choices-in-methods-for-economic-evaluation."}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-026-01625-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-026-01625-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-026-01625-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T08:01:55Z","timestamp":1784188915000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-026-01625-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":134,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["1625"],"URL":"https:\/\/doi.org\/10.1007\/s40273-026-01625-0","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,1]]},"assertion":[{"value":"28 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MF, RST and PP declare no conflicts of interest. JF received consultancy funding to support the design and conduct of the systematic review, paid to his employer, and is Chair of NICE Technology Appraisal Committee C. JJGS, LR, JC and PGDF are employees and shareholders of AstraZeneca. AG and PC are, or were employees of HEOR Ltd, who are paid consultants to AstraZeneca in connection with the development of this manuscript.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The data sets generated during and\/or analysed during the current review are available from the corresponding author on reasonable request.","order":3,"name":"Ethics","label":"Data availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors contributed to the development of the study protocol. AG and PC conducted the screening, data extraction and synthesis of the SLR. All authors contributed to the interpretation of data, preparation and review of the manuscript, and gave approval of the final manuscript for publication.","order":4,"name":"Ethics","label":"Author contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}